Researchers at VIB have created oral antibodies through a yeast or soybean manufacturing process, making it easy to administer medication to animals. These antibodies have been shown to protect piglets from enterotoxigenic Escherichia coli (ETEC) infection, providing a sustainable option to antibiotics in animal agriculture. This success has led to the establishment of the company Animab.

VIB’s mission is to conduct frontline biomolecular research in life sciences for the benefit of scientific progress and the benefit of society.

Starting from ideas or discoveries conceived in the VIB labs, the New Ventures team builds new biotech ventures. First off, the team will build a solid data package, obtain proof of concept (PoC) and define a solid IP strategy.